Immunosupression tailoring based on individual peculiarity of hcv-infection
Abstract
The capability of HCV infection to induce glomerular damage and to compromise host immunity is well known. We’ve investigated the possibility to improve outcome in HCV-infected kidney allograft recipients by immunosupression tailoring, based on HCV features. Forty one cadaver kidney allograft recipients were followed up during 38,8 ± 15 months. Three-year patient and graft survival rates are 95% and 93%. Graft function, evolution of anti-HCV and HCV-RNA and liver function tests, as well as immunosupression change are analyzed and discussed. Evidence-based therapy tailoring leads to save and effective immunosupression management in kidney transplantation.
About the Authors
M. M. Kaabak
Российский научный центр хирургии Российской академии медицинских наук, Москва
Russian Federation
Russian Federation
T. Yu. Cheprasova
Российский научный центр хирургии Российской академии медицинских наук, Москва
Russian Federation
Russian Federation
N. N. Babenko
Российский научный центр хирургии Российской академии медицинских наук, Москва
Russian Federation
Russian Federation
References
1. Зубкин М.Л., Селиванов Н.А., Стаханова В.М. и соавт. Особенности инфицирования больных на гемодиализе вирусами гепатитов В и L. Трансплант. и искусств. органы 1998; 4: 54-57.
2. Зубкин М.Л. Вирусные гепатиты. Особенности в условиях заместительной терапии хронической почечной недостаточности. Нефрология и диализ 1999; 1: 4-11.
3. Назаров Ш.Н., Акалаев Р.Н., Аринходжаева Ф.А., Миркамалов А.А. Проблемы вирусного гепатита в отделениях гемодиализа. Микробиол. Эпидемиол. Иммунобиол. 1993; 2: 71-73.
4. Савин Е.А. В кн.: Вирусные гепатиты (частные аспекты проблемы). СПб.: Наука 1996; 85-94, 115-120.
5. Baid S., Pascual M., Williams W.W. et al. Renal thrombotic microangiopathy associated with anticardiolipin antibodies in hepatitis C-positive renal allograft recipients. J Am Soc Nephrol 1999; 10: 146-153.
6. Batty D.S.J., Swanson Jr.S., Kirk A.D., Ko C.W., Agodoa L.Y., Abbot K.C. Hepatitis C virus seropositivity at the time of renal transplantation in the United States: associated factors and patient survival. American Journal of Transplantation 2001; V1; 2: 179-184.
7. Cirocco R.D., Zucker K.R. et al. De novo membranoproliferative glomerulonephritis in hepatitis C virus-infected renal allograft recipients. Transplantation 1995; 59: 1676-1682.
8. Cosio F.G., Sedmak D.D., Henry M.L. et al. The high prevalence of severe early posttransplant renal allograft pathology in hepatitis C positive recipients. Transplantation 1996; 62: 1054-1059.
9. Cruzado J.M., Torras J., Gli-Vernet S. et al. Glomerulonephritis associated with hepatitis C virus infection after renal transplantation. Nephrol Dial Transplant 2000; RJ 15 (Suppl 8): 65-67.
10. Cruzado J.M., Gli-Vernet S. et al. Hepatitis C virus-associated membranoproliferative glomerulonephritis in renal allografts. J Am Soc Nephrol 1996; 7: 2469-2475.
11. Cruzado J.M., Carrera M., Torras J., Grinyу J.M. Hepatitis C virus infection and de novo glomerular lesions in renal allografts. American Journal of Transplantation July 2001; 1; 2: 171-178.
12. Hestin D., Guillemin F., Castin N., LeFaou A., Champigneulles J., Kessler M. Pretransplant hepatitis C virus infection. A predictor of proteinuria after renal transplantation. Transplantation 1988; 65: 741-744.
13. Johnson Gretch D.R., Yamble H. et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med 1993; 328: 465-470.
Review
For citations:
Kaabak M.M., Cheprasova T.Yu., Babenko N.N. Immunosupression tailoring based on individual peculiarity of hcv-infection. Nephrology and Dialysis. 2004;6(3):238-242. (In Russ.)
Views:
6
Email this article 